Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SKAN Group AGFRA:7VG -0.84%66 EV-to-EBIT is 59.98 as of Jul. 27, 2026, which is 21% above its 10-year median of 49.39. GuruFocus rates FRA:7VG with a GF Score™ of 66/100 and a GF Value™ of €91.63 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 466 Medical Devices & Instruments companies, SKAN Group AG ranks worse than 89.27% on this metric.
The historical rank and industry rank for SKAN Group AG's EV-to-EBIT or its related term are showing as below:
FRA:7VG'
s EV-to-EBIT Range Over the Past 10 Years
Min: 20.89 Med: 49.39 Max: 71.09
Current: 59.79
During the past 6 years, the highest EV-to-EBIT of SKAN Group AG was 71.09. The lowest was 20.89. And the median was 49.39.
FRA:7VG's EV-to-EBIT is ranked worse than 89.27% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 18.395
vs FRA:7VG: 59.79
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
SKAN Group AG's Enterprise Value for the quarter that ended in Dec. 2025 was €1,302.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SKAN Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €24.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SKAN Group AG EV-to-EBIT Related Terms
SKAN Group AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for SKAN Group AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, SKAN Group AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SKAN Group AG EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SKAN Group AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where SKAN Group AG's EV-to-EBIT falls into.
SKAN Group AG's current Enterprise Value is €1,438.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SKAN Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €24.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SKAN Group AG (FRA:7VG) has a EV-to-EBIT of 59.98 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SKAN Group AG and its competitors. This is 21% above median its historical median of 49.39. Over the past decade, SKAN Group AG's EV-to-EBIT has ranged from 20.89 to 71.09. According to the industry distribution chart, SKAN Group AG ranks #416 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 89.3%.
Is SKAN Group AG's EV-to-EBIT too high?
SKAN Group AG's current EV-to-EBIT of 59.98 is 21% above median its 10-year median of 49.39. Over the past 10 years, this metric has ranged from a low of 20.89 to a high of 71.09. The Medical Devices & Instruments industry median EV-to-EBIT is 18.40. SKAN Group AG's value of 59.98 is 226.1% above this industry median. Based on the distribution chart, SKAN Group AG ranks #416 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, SKAN Group AG has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SKAN Group AG's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, SKAN Group AG ranks #416 out of 466 companies for EV-to-EBIT. This places SKAN Group AG in the lower half of its industry. The industry median EV-to-EBIT is 18.40. SKAN Group AG's value of 59.98 is 226.1% above this benchmark. Historically, SKAN Group AG's own EV-to-EBIT has ranged from 20.89 to 71.09 over the past decade. While the company's 10-year median is 49.39 vs. the industry median of 18.40, SKAN Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.40, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SKAN Group AG's current EV-to-EBIT of 59.98 is 226.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SKAN Group AG and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SKAN Group AG's current EV-to-EBIT is 59.98, which is 21% above median its own 10-year median of 49.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SKAN Group AG stock overvalued right now?
Based on GuruFocus' analysis, SKAN Group AG (FRA:7VG) is currently considered Significantly Undervalued. The stock's GF Value™ is €91.63, compared to a current price of €59.00 — trading 35.6% below its estimated fair value. The current EV-to-EBIT is 59.98, which is 21% above median its 10-year median of 49.39 and 226.1% above the Medical Devices & Instruments industry median of 18.40. SKAN Group AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For SKAN Group AG (FRA:7VG), the current EV-to-EBIT is 59.98 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SKAN Group AG (FRA:7VG) Overvalued in 2026?
Based on GuruFocus' analysis, SKAN Group AG stock appears to be undervalued.
The current stock price of €59.00 is trading 35.6% below its estimated GF Value™ of €91.63.
GuruFocus considers SKAN Group AG to be Significantly Undervalued.
Key valuation signals for FRA:7VG:
EV-to-EBIT: 59.98 (21% above median its 10-year median of 49.39)
GF Value™: €91.63 vs. price of €59.00 (35.6% below fair value)
Industry Position: 226.1% above the Medical Devices & Instruments median (#416 of 466)
No single metric tells the full story. See the FRA:7VG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SKAN Group AG is a market and technological company for isolators, cleanroom devices, and decontamination processes for the aseptic production of biopharmaceutical substances. The company offers its customers process support, services, and consumables. Its products include biological indicators, isolators, Laboratory/cleanroom equipment, laminar flow, safety workbenches, transfer systems, and others. The Firm has three operating segments: Equipment & solutions, Services & Consumables, and Other. The company generates the majority of its revenue from the Equipment & solutions segment. Geographically, the company derives revenue from Asia, Europe, Americas, and Other regions.
66GF Score
Get the complete analysis for FRA:7VG
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VG has been successfully added to your 
